Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the publication of a patent application by the USPTO for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing binge behavior disorders.
The patent application stems from Clearmind’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC). This therapy targets multiple binge behaviors, including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct. The combination leverages MEAI’s neuroplastic properties to reduce impulsivity and reward-seeking behavior, which, together with PEA, has shown a synergistic pharmacological effect and therefore potentially offering a breakthrough in treating substance use disorders and addictions by presenting a more effective and safer treatment than those available today.
In a statement, Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “The publication of this U.S. patent application represents yet another advancement in our mission to pioneer safe and effective, next-generation treatments for binge behaviors. By combining MEAI’s unique neuroplastic profile with PEA’s synergistic benefits, we’re aiming to address a significant unmet need in addiction medicine. We believe that this strengthens our position as a leader in psychedelic therapeutics and paves the way for additional clinical development.”
